The study of dyslipidemia and its correlation with nephropathy in diabetes mellitus type 2 patients

Rakesh K. Sisodia, Archana Gupta, Neelima Singh


Background: Diabetic nephropathy is one of the most severe diabetic microangiopathies. The aim of this study was to evaluate the lipid abnormalities associated with different stages of proteinuria in type 2 diabetic patients.

Methods: In this study 100 type 2 diabetic patients were subjected to detailed history, clinical examination, Serum lipid profile, urine albumin creatinine ratio and routine biochemical investigations.

Results: Out of 100 patients were included in study, 41 patients were normoabluminuric, 37 patients were microalbuminuric and 22 patients were overt proteinuric. Most common dyslipidemia found in study is increased triglyceride (43%) followed by increased LDL (28). On comparing normoalbuminuric to overt proteinuric, a positive correlation found in increased triglyceride (P value < 0.001) and increases LDL (P value <0.001).

Conclusions: Concluded that raised Triglyceride and LDL are associated with Diabetic Nephropathy.


Albuminurea, Diabetes type 2, Dyslipedemia, Diabetic nephropathy, Proteinurea

Full Text:



Wheeler DC, Fernando TL, Gillett MPT, Davies M, Williams JD. Numbers and letters correspond to the affiliation list. Click to expose these in author workspace. Author links open the author workspace characterization of the binding of low density lipoproteins to cultured rat mesangial cells. Nephrol Dial Transplant. 1991;6:701-8.

Gröne HJ, Walli A, Gröne E, Krämer A, Clemens MR, Seidel D. Receptor mediated uptake of apo B and apo E rich lipoproteins by human glomerular epithelial cells. Kidney Int. 1990;37:1449-59.

Takemura T, Yoshioka K, Aya N, Murakami K, Matumoto A, Itakura H, et al. Apolipoproteins and lipoprotein receptors in glomeruli in human kidney-diseases. Kidney Int. 1993;43:918-27.

Guijarro C, Kasiske BL, Kim Y, O’Donnell MP, Lee HS, Keane WF. Early glomerular changes in rats with dietary-induced hypercholesterolemia. Am J Kidney Dis. 1995;26:152-61.

Pesek-Diamond I, Ding G, Frye J, Diamond JR. Macrophages mediate adverse effects of cholesterol feeding in experimental nephrosis. Am J Physiol. 1992;263:F776-783.

Schlondorff D. Cellular mechanisms of lipid injury in the glomerulus. Am J Kidney Dis. 1993;22:72-82.

Gröne HJ, Walli AK, Gröne EF. The role of oxidatively modified lipoproteins in lipid nephropathy. Contrib Nephrol. 1997;120:160-75.

Gilbert RE, Cooper ME. The tubulointerstitium in progressive diabetic kidney disease: More than an aftermath of glomerular injury? Kidney Int. 1999;56:1627-37.

Cooper ME. Pathogenesis, prevention, and treatment of diabetic nephropathy. Lancet. 1998;352:213-9.

Struder RK, Craven PA, De Rubertis FR. Low-density lipoprotein stimulation of mesangial cell fibronectin synthesis: Role of protein kinase C and transforming growth factor-. J Lab Clin Med. 1995;125:86-95.

Ding G, van Goor H, Ricardo SD, Orlowski JM, Diamond JR. Oxidized LDL stimulates the expression of TGF-beta and fibronectin in human glomerular epithelial cells. Kidney Int. 1997;51:147-54.

Ding G, Pesek-Diamond I, Diamond JR. Cholesterol, macrophages, and gene expression of TGF-1 and fibronectin during nephrosis. Am J Physiol. 1993;264:F577-584.

Bank N, Aynedjian HS. Role of thromboxane in impaired renal vasodilatation response to acetylcholine in hypercholesterolemic rats. J Clin Invest. 1992;89:1636-42.

Gröne HJ, Hohbach J, Gröne EF. Modulation of glomerulosclerosis and interstitial fibrosis by native and modified lipoprotein. Kidney Int. 1996;49(suppl. 54):18-22.

Remuzzi G, Ruggenenti P, Benigni A. Understanding the nature of renal disease progression. Kidney Int. 1997;51:12-5.

American Diabetes Association: Standards of medical care for patients with diabetes mellitus (Position Statement). Diabetes Care. 2002;25(Suppl. 1):S33-S49.

National Cholesterol Education Program. Third Report of the expert panel on detection, Evaluation, and Treatment of HighBlood Cholesterol in Adults (Adult Treatment Panel III) Bethesda: National Heart, Lung and Blood Institute; 2001.

Afghahi H, Cederholm J, Eliasson B, Zethelius B, Gudbjörnsdottir S, Hadimeri H, et al. Risk factors for the development of albuminuria and renal impairment in type 2 diabetes-the Swedish National Diabetes Register (NDR). Nephrol Dial Transplant. 2011;26:1236-43.

Smulders YM, Rakic M, Stehouwer CDA, Weijers RNM, Slaats EDH, Silberbusch J. Determinants of progression of microalbuminuria in patients with NIDDM. Diabetes Care. 1997;20(6):999-1005.

Yang X, So WY, Ma R, Ko G, Kong A, Lam C, et al. Effects of albuminuria and renal dysfunction on development of dyslipidaemia in type 2 diabetes-the Hong Kong Diabetes Registry. Nephrol Dial Transplant. 2008;23:2834-40.

Ravid M, Brosh D, Safran DR, Levy Z, Rachmani R. Main risk factors for nephropathy in type 2 diabetes mellitus are plasma cholesterol levels, mean blood pressure, and hyperglycemia. Arch Intern Med. 1998;158:1001.

Patel ML, Sachan R, Gupta KK, Uniyal R. Correlation of plasma apolipoprotein and lipid profiles with different stages of type 2 diabetic nephropathy-a hospital based study in North Indian Population. Int J Scien Res Publi. 2012;2(5):ISSN 2250-3153.

Jha P, Das BK, Shrestha S, Majhi S, Chandra L, Sharma S, et al. Glycemic status, lipid profile and proteinuria in diabetic nephropathy. JNMA J Nepal Med Assoc. 2010;49(178):143-6.

Retnakaran R, Cull CA, Thorne KI. UKPDS study group. Risk factors for renal dysfunction in type 2 diabetes: U.K. Prospective Diabetes Study 74. Diabetes. 2006;55:1832-9.

Hasslacher C, Bostedt-Kiesel A, Kempe HP, Wahl P. Effect of metabolic factors and blood pressure on kidney function in proteinuric type 2 (non-insulin-dependent) diabetic patients. Diabetol. 1993;36:1051-6.